Healthcare >> CEO Interviews >> October 12, 2001
BASSIL DAHIYAT, is co-Founder, President and CEO of Xencor as well as
co-inventor of the PDA_ technology. He has been CEO since the
incorporation of the company in August 1997. Dr. Dahiyat raised Xencor's
financing, executed exclusive license agreements with Caltech for the
Protein Design Automation_ technology and Johns Hopkins for the ProCode_
technology, established company facilities and staffing and conceived
and implemented Xencor's research and development program. Dr. Dahiyat
manages the company's research activities as CSO and directs an
aggressive patent strategy for Xencor's technology platform and
proprietary proteins. Dr. Dahiyat holds a PhD in Chemistry from Caltech
and BS and MSE degrees in Biomedical Engineering from The Johns Hopkins
University. Dr. Dahiyat has co-authored numerous scientific papers in
the fields of protein design and drug delivery and has received
scientific awards from the American Chemical Society, the Controlled
Release Society, the Protein Society, and Caltech. Profile
Xencor?
Dr. Dahiyat: We were founded in late 1997 to commercialize technology
developed at the California Institute of
